Weight loss medications on exercise capacity in Pulmonary Arterial Hypertension (PAH) patients

Glucagon-like peptide (GLP-1) Agonist for Patients with Overweight or Obesity and Pulmonary Arterial Hypertension (GO-PAH): An Open-Label Multicentre Proof-of-Concept Study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12626001139369

Acronym

GO PAH

Enrollment

Registered

2026-09-14

Start date

2026-10-12

Completion date

2027-08-31

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This clinical trial that looks at the effect of a weight loss medication (Semaglutide, more commonly known as Wegovy or Ozempic) on improving the exercise ability in patients with pulmonary arterial hypertension who have an elevated body mass index (BMI)

Interventions

Medication: Semaglutide Dose: 2.4mg weekly for 52 weeks Mode: subcutaneous injection Strategies to monitor adherence: dispensing history, return penfill syringes

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Body mass index (BMI) equal to or greater than 27 kg/m² 2. Able to provide written consent 3. Confirmed WHO Group 1 PAH, diagnosed by right heart catheterisation (RHC) 4. Stable background PAH-specific therapy for equal to or greater than 90 days prior to enrollment 5. Baseline haemodynamics (on most recent RHC): Mean pulmonary arterial pressure (mPAP) equal to or greater than 25 mmHg, Pulmonary arterial wedge pressure (PAWP) less than 15 mmHg, Pulmonary vascular resistance (PVR) equal to or greater than 4 Wood units 6. 6 minute walk distance between 100-550 meters 7. Systolic blood pressure equal to or greater than 95 mmHg

Exclusion criteria

1. Type 1 diabetes mellitus 2. Use of GLP-1 receptor agonists or dual incretin therapies within the previous 3 months or planned bariatric surgery within 12 months 3. Known drug allergy to incretins or any contraindication to semaglutide as per product label 4. Active eating disorder or history of pancreatitis 5. Personal and/or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) 6. Severe gastrointestinal disease (e.g. gastroparesis, IBD) limiting drug tolerability 7. Pregnancy, breastfeeding, or unwillingness to use effective contraception 8. Severe hepatic impairment or renal impairment (eGFR less than 30 mL/min/1.73 m²) 9. Unstable cardiovascular disease (recent MI, unstable arrhythmia, decompensated HF) 10. Life expectancy less than 12 months or expected need for lung transplantation in next 12 months 11. Suicidal ideation in the last 90 days or a history of suicide attempts

Outcome results